Select Page

Tarrytown, NY, November 7, 2007 – PsychoGenics Inc. today announced that it has entered into a drug discovery agreement with Cephalon, Inc. The agreement provides that Cephalon will supply compounds that are prospectively suitable for neuropsychiatric disorders to PsychoGenics for evaluation using its proprietary drug discovery technologies.